All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy of Transfer Factor TFI Treatment by Assessing the Number of New Infections in Subjects with Recurrent Respiratory or Urinary Tract Infections or Recurrent Herpetic Infections Recorded over a Period of 6 Months from Randomization

Living with repeat infections can be painful, exhausting, and disruptive to daily life. This Phase 3 clinical study is evaluating a potential treatment called Transfer Factor TFI. Researchers want to find out whether it can lower the number of new infections in adults who regularly suffer from chest infections, urinary tract infections (UTIs), or recurrent herpes outbreaks, such as cold sores. Participants will be placed by chance into one of two groups: one group will receive Transfer Factor TFI, and the other will receive a harmless dummy treatment called a placebo. Neither the participants nor the study doctors will know who is taking which treatment during the study. Over six months, doctors will monitor everyone's health and count any new infections that occur. The findings will help doctors understand if this treatment can successfully support the immune system.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Aumed a.s.
Enrolment target
100
Start
08 Jan 2025

What is this study about?

Frequent infections—such as chest colds that will not go away, painful urinary tract infections (often called water infections or cystitis), or recurrent cold sores—can be very challenging to manage. While standard medications like antibiotics or antivirals can treat an active infection, they do not always prevent the next one from returning.

This clinical study is investigating a treatment called Transfer Factor TFI. Transfer factors are natural molecules that help the body's immune system recognise, respond to, and remember specific bugs. Researchers hope that by giving this treatment, they can train the immune system to fight off germs more effectively, reducing how often people become unwell.

To ensure the findings are trustworthy, the study is randomised and double-blind. This means participants will receive either Transfer Factor TFI or an identical-looking dummy treatment (placebo), chosen by computer. Neither you nor your study team will know which one you are taking until the trial ends. Over a six-month period, doctors will track your symptoms to see if those taking the real medicine experience fewer infections than those taking the placebo.

If the study shows positive results, it could provide a new way to help people build stronger protection against persistent, recurring illnesses, potentially reducing the need for repeated courses of antibiotics.

Key takeaways

  • Tests whether Transfer Factor TFI helps prevent recurring infections.
  • Open to adults aged 18 and older with frequent chest, urinary, or herpes infections.
  • Compares the active treatment against an inactive dummy treatment (placebo).
  • Involves tracking your infections and attending health checks over six months.
  • Taking part is completely voluntary and you can stop at any time.

Who may be eligible?

This trial is open to men and women aged 18 and over who regularly deal with repeat infections. This includes people who experience frequent respiratory infections (such as repeated chest or throat infections), recurrent urinary tract infections (UTIs), or recurring herpes infections (such as frequent cold sores or genital herpes).

To take part, you will need to have a documented history of these recurring conditions and be able to commit to the study for six months. You will also need to be willing to record your symptoms and attend scheduled health check-ups.

Certain people may not be able to join, such as those with specific underlying immune conditions or those taking medications that alter the immune system. The study doctor will review your medical records with you to check whether it is safe and suitable for you to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I frequently get chest or throat infections.
  3. OR I frequently get urinary tract infections (UTIs/cystitis).
  4. OR I frequently get herpes outbreaks (such as cold sores).
  5. I am able to attend clinic visits and keep track of my symptoms for six months.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for six months. If you decide to join, you will first attend a screening visit to check your general health and confirm that the study is right for you. You will then be randomly assigned to take either Transfer Factor TFI or a placebo. You will take the assigned treatment as directed by the research team. Throughout the six months, you will be asked to keep a simple record of any infection symptoms you experience. You will attend regular clinic appointments or check-ins where doctors will examine you, review your symptom diary, and check for any side effects. Standard medical treatment will always be available if an infection does flare up.

Potential risks and benefits

You may benefit from a reduction in how often you get infections, but this cannot be guaranteed, particularly if you are in the group receiving the dummy treatment. However, your participation will help doctors find better ways to protect people from recurrent illnesses in the future. As with any medical treatment, there is a risk of unwanted side effects or allergic reactions, which the study team will explain and closely monitor. Joining the study is entirely voluntary, and you are free to leave at any time without giving a reason and without it affecting your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Czechia

Common questions

What is Transfer Factor TFI?

It is a treatment made from natural immune molecules that help teach your body's defence system how to spot and fight off specific germs.

What is a placebo?

A placebo is an inactive dummy treatment that looks and tastes exactly like the real medicine, used to ensure the study results are fair and unbiased.

Will I know if I am getting the real treatment or the placebo?

No. The trial is double-blind, meaning neither you nor the study team will know which one you are taking until the study is completely finished.

What happens if I get an infection during the study?

You will still receive prompt, standard medical care to treat the illness. You will simply report the infection to the study team so they can record it.

Does taking part cost anything?

No. All study-related medicines, tests, and doctor visits are provided free of charge, and you will not be asked to pay to take part.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Randomized, Double-Blind, Placebo-Controlled Clinical Tria…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.